Mental illnesses represent a small group in comparison to other therapeutic areas. Up until this time, xx medicinal products have been assessed in xx resolutions on illnesses such as schizophrenia, depression or ADHD. Of the subpopulations, xx% have seen a major additional benefit, XX% a considerable, XX% a minor and XX% a non-quantifiable additional benefit. The G-BA could see no additional benefit for XX% of the subpopulations weighted according to their share of patients in the respective resolution, corresponding to xx% of the maximum number of xx million patients treatable with these medicinal products.